Publication | Closed Access

Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors

Therapeutic EffectAutoimmune DiseaseBlood–brain BarrierMedicinePharmacologyImmunologyExperimental Autoimmune EncephalomyelitisBlood-brain BarrierAutoimmunityAutoantibodiesBrain InjuryNeuroprotectionNeurologyMultiple SclerosisCerebral Blood FlowBrain-immune InteractionNeuroimmunologyNeuroinflammation